Status:

TERMINATED

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Leukemia

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this clinical research study is to compare the rate of complete cytogenetic response of dasatinib to imatinib therapy at 6 months after randomization in chronic phase CML patients. The ...

Eligibility Criteria

Inclusion

  • Men and women ≥18 years diagnosed with Chronic Phase Philadelphia chromosome positive (CP Ph+) CML who have failed to achieve CCyR after 3-18 months of therapy with imatinib 400 mg
  • Treatment initiation with imatinib 400 mg within 6 months of initial CML diagnosis
  • Able to tolerate chronic administration of imatinib at the highest dose (400-600 mg) the subject has received in the past
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2
  • Adequate hepatic and renal function

Exclusion

  • Eligible and willing to undergo immediate autologous/allogeneic stem cell transplant
  • Previous diagnosis of accelerated/blast crisis CML
  • Subjects with clonal evolution in Ph+ cells observed in ≥2 metaphases
  • Previous documentation of T315I mutation
  • Uncontrolled or significant cardiovascular disease
  • Serious uncontrolled medical disorder/active infection
  • History of significant bleeding disorder unrelated to CML
  • Intolerance to imatinib ≥400 mg
  • Concurrent malignancies other than CML

Key Trial Info

Start Date :

April 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2008

Estimated Enrollment :

3 Patients enrolled

Trial Details

Trial ID

NCT00362466

Start Date

April 1 2007

End Date

June 1 2008

Last Update

November 20 2009

Active Locations (45)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 12 (45 locations)

1

Dr. Marshall Schreeder

Huntsville, Alabama, United States, 35805

2

Local Institution

Little Rock, Arkansas, United States, 72205

3

Local Institution

Alhambra, California, United States, 91801

4

Local Institution

Anaheim, California, United States, 92801